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Abstract – The concise synthesis of the 
3,7-dihydroxy-2,5,8,8-tetramethylnonanoic acid moiety of apratoxin A and the 
total synthesis of compound 3, a 4-biphenylalanine (Bph) analogue of apratoxin A, 
have been demonstrated. The Bph analogue 3 exhibited a 16-fold increase in 
cytotoxicity against HCT-116 cells with respect to apratoxin A. This evidence 
indicated that existing the 4-phenyl group of Bph in 3 significantly enhanced its 
cytotoxicity, a conclusion corroborated by the 100-fold difference in cytotoxicity 
against HCT-116 cells observed between apratoxin M7 and apratoxin M16, which 
is characterized by the presence of a 4-phenyl group where apratoxin M7 displays 
a 4-methoxy group. Results from a conformational study using a distance 
geometry method suggested that 3 and apratoxin A adopt similar conformations in 
CD3CN.
Apratoxin A (1) isolated from the marine cyanobacterium Lyngbya majuscula exhibits potent cytotoxicity 
against various cancer cell lines and in vivo anticancer activity (Figure 1).1–3 Recently, its analogues, 
apratoxins S4, S8, and S10 that lack a Michael acceptor existing in apratoxin A have been extensively 
studied by Luesch et al. as antitumor agents without causing lethal toxicity.4 
We have recently reported that apratoxin M7 (2a), which can be viewed as a derivative of apratoxin A in 
which a piperidine-4-carboxylic acid moiety has replaced apratoxin A’s modified cysteine moiety, 
exhibited potent cytotoxicity against HCT-116 cancer cells with an IC50 value of 120 nM. Further 
modification of the compound consisting in the replacement of Tyr(Me) with Phe, Phe(4-Cl), and 
 
4-biphenylalanine (Bph) resulted in the syntheses of apratoxins M14, 15, and 16 (2b–2d), respectively.5 
Interestingly, evidence indicated that the identity of the substituent R (H, Cl, or Ph) affected the 
cytotoxicity of 2b–2d against HCT-116 cells. In particular, the Bph derivative of 2a, apratoxin M16 (2d) 
displayed a 100-fold increase in potency with respect to 2a, with a measured IC50 value of 1.1 nM, which 
of the same order of magnitude as that of apratoxin A. Results from a conformational analysis performed 
on apratoxins M7 and M16 using a distance geometry method based on NMR spectroscopy data indicated 
that both analogues have similar conformations to that of apratoxin A. These results led us to plan the 
synthesis of a new Tyr(Me)/Bph analogue of apratoxin A 3 to investigate whether the replacement of the 
methoxy group on Tyr(Me) in the parent compound apratoxin A with a 4-phenyl substituent is an 
effective approach to causing the IC50 value against HCT-116 cells to decrease. Thus, we synthesized 
compound 3 via the concise asymmetric synthesis of a 3,7-dihydroxy-2,5,8,8-tretramethylnonanoic acid 
(Dtena) moiety and discovered that 3 exhibited a much more potent activity than 1 against HCT-116 cells. 
 
  
Figure 1. The structures of apratoxin A (1), its analogues 2a–2d, and the newly synthesized analogue 3, 
and the reported IC50 values against HCT-116 cells. 
 
Although the total synthesis of apratoxin A has been reported in several papers,6 we planned to perform 
the concise synthesis of 7 by way of a modification of the synthesis of apratoxin C, which we reported 
previously.7 The optically active mono-acid 4, obtained from the enzymatic alcoholysis of 
3-methylglutaric anhydride, was quantitatively transformed into tert-butyl ketone 5 via acid chloride 
formation, followed by copper-mediated addition of a tert-butyl Grignard reagent (Scheme 1). The 
(R)-2-methyl-CBS-oxazaborolidine-catalyzed stereoselective reduction of ketone 5 was then investigated 
(Table 1).8 This reaction was performed at 0 °C using BH3•THF to provide compound 6 in 57–59% 
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catecholborane as stoichiometric reductant resulted in high stereoselection (Entries 3–6)8 with the best 
result being obtained when 5 equivalents of catecholborane were utilized. The desired compound 6 was 
produced in 88% yield and 99% stereoselectivity (Entry 5). 4-Methoxyphenylmethyl (MPM) protection 
of 6 using 2,4,6-tris(4-methoxybenzyloxy)-1,3,5-triazine (TriBOT-PM)9 and reduction of the propyl ester 
moiety afforded alcohol 7, which was converted to the synthetic intermediate 8 through the published 
procedure.10,11  
 
Scheme 1. Concise synthesis of alcohol 7 for the preparation of compound 8. 
 
Table 1. Applied conditions and results of the CBS reduction of ketone 5 to produce compound 6. 
Entry Borane reagenta Equivalents Concentration of 5 (M) Time (h) Yield
b (%) drc 
1 BH3•THF 1.0  0.33 0.75 59 85:15 
2 BH3•THF 1.0  0.09 11 57 90:10 
3 Catecholborane 1.5  0.15 9.5 9 97:3 
4 Catecholborane 3.0  0.13 15 83 98:2 
5 Catecholborane 5.0  0.15 9 88 99:1 
6 Catecholborane 10.0  0.08 14 79 99:1 
aTHF solution. bCombined yield. cThe diastereomeric ratio of 6 was determined by HPLC. 
 
The synthesis of 3 was carried out in a similar manner to the synthesis of apratoxin A 12 (Scheme 2). 
Removal of the allyl group in 8 (cat. Pd(PPh3)4/PhNHMe/THF), followed by coupling of the resulting 
acid with tripeptide 913 (HATU/DIEA/CH2Cl2) provided the desired product 10 in 99% yield over two 
steps. The sequential removal of the protecting groups at the C and N termini of 10, followed by 
macrolactamization under high dilution conditions (HATU/DIEA/CH2Cl2/1 mM) furnished the apratoxin 
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A’s Bph analogue 3 in 35% overall yield. The cytotoxicities of 3 and 1 against HCT-116 cells were then 
evaluated side-by-side. The IC50 for 3 was found to have a value of 0.20 nM, corresponding to a 16-fold 
increase in potency with respect to apratoxin A (IC50: 3.3 nM). Notably, the 4-phenyl substituent of Bph 
greatly increased the cytotoxicity toward HCT-116 cells of the parent compound apratoxin A similarly to 
what had been observed for apratoxin M16.5  
 
 
Scheme 2. Synthesis of compound 3, the 4-biphenylalanine analogue of apratoxin A. 
 
The 3D structure of 3 in CD3CN was analyzed by a distance geometry method based on NMR spectral 
data (Table 2). Results from this analysis suggest that the 3D structure of 3 is almost identical to that of 
apratoxin A (Figure 2), indicating that the substitution of apratoxin A’s Tyr(Me) with Bph did not induce 
any conformational change, although it significantly increased the compound’s cytotoxicity against 
HCT-116 cells. Given that Huang et al. have reported that a D-Tyr(Me) analogue of apratoxin A does not 
exhibit cytotoxicity against A2058 cells,3 it is conceivable that the 4-methoxyphenyl group of Tyr(Me) of 
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this target molecule could be further enhanced by replacing the 4-methoxyphenyl group of apratoxin A 
with a 4-biphenyl group. 
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Figure 2. Superposition of the lowest energy conformers of apratoxin A’s 4-biphenylalanine analogue 3 
(structure in green) and apratoxin A (1) (structure in yellow) obtained by a conformational analysis 
performed using a distance geometry method. 
 
In summary, we have demonstrated a concise synthesis of the Dtena moiety and the total synthesis of the 
apratoxin A’s Bph analogue 3. Biological evaluation indicated the 4-phenyl group of Bph in 3 caused the 
compound’s cytotoxicity against HCT-116 cells to increase substantially with respect to apratoxin A. A 
similar trend, in this case with respect to apratoxin M7’s cytotoxicity versus HCT-116 cells, was observed 
in the case of apratoxin M16 (2d). Results from a conformational study performed using a distance 
geometry method suggest that 3 and apratoxin A (1) adopt similar conformations in CD3CN. These 
results should provide important structure-activity relationship information that could be used in the 
future design of useful apratoxin A analogues. 
 
EXPERIMENTAL  
General. All commercially available reagents were used as received. Dry THF and CH2Cl2 (Kanto 
Chemical Co.) were obtained by passing commercially available pre-dried, oxygen-free formulations 
through activated alumina column. All reactions in the solution phase were monitored by TLC carried out 
on Merck silica gel plates (0.2 mm, 60F-254) with UV light, and visualized by p-anisaldehyde 
H2SO4−EtOH solution or phosphomolybdic acid−EtOH solution or ninhydrin−AcOH−1-BuOH solution. 
Silica gel 60N (Kanto Chemical Co. 100~210 mm) was used for column chromatography. SHIMADZU 
LC-10AT and Shodex RI-101 were used for normal-phase HPLC analysis. Waters 1525 binary pump and 
Waters 2489 UV/visible detector were used for reversed-phase HPLC purification of the final product. 1H 
NMR spectra (400 and 600 MHz) and 13C NMR spectra (100 and 150 MHz) were recorded on JEOL 
JNM-AL400 and JEOL JNM-ECA600 spectrometers in the indicated solvent. Chemical shifts (δ) are 
reported in units parts per million (ppm) relative to the signal for internal TMS (0.00 ppm for 1H) for 
solutions in CDCl3. NMR spectral data are reported as follows: chloroform (7.26 ppm for 1H) or 
chloroform-d (77.0 ppm for 13C), dichloromethane (5.32 ppm for 1H) or dichloromethane-d2 (53.8 ppm 
for 13C), and acetonitrile (1.94 ppm for 1H) or acetonitrile-d3 (118.26, 1.32 ppm for 13C) when internal 
standard is not indicated. Multiplicities are reported by the following abbreviations: s (singlet), d 
(doublet), t (triplet), q (quartet), m (multiplet), dd (double doublet), brs (broad singlet), brd (broad 
doublet) and J (coupling constants in Hertz). High-resolution mass spectra were measured on Thermo 
Scientific™ Exactive™ Plus Orbitrap Mass Spectrometer (for ESI). IR spectra were recorded on a 
JASCO FTIR-4100. Only the strongest and/or structurally important absorption are reported as the IR 
data afforded in wavenumbers (cm−1). Specific rotations were measured on a JASCO P-1010 polarimeter. 
 
Propyl (R)-3,6,6-trimethyl-5-oxoheptanoate (5): To a solution of the carboxylic acid 47 (1.00 g, 5.31 
mmol, 1.0 equiv) in dry CH2Cl2 (11 mL) were added DMF (20.0 µL, 0.260 mmol, 0.05 equiv) and 
(COCl)2 (690 µL, 7.96 mmol, 1.5 equiv) at 0 °C under an argon atmosphere. After being stirred at the 
same temperature for 1 h, the reaction mixture was concentrated in vacuo. The resulting crude acid 
chloride was used for the next reaction without further purification. 
  To an oven-dried flask were added LiBr·H2O (2.68 g, 25.5 mmol, 4.8 equiv) and CuBr (1.82 g, 12.7 
mmol, 2.4 equiv), and the flask was dried using a heat-gun under vacuum. Once the flask had cooled, dry 
THF (15 mL) was added, and the suspension was cooled to −78 °C under an argon atmosphere. To the 
green suspension was added a solution of t-BuMgCl (12.7 mL, 12.7 mmol, 1.0 M in THF, 2.4 equiv), 
followed immediately by addition of a solution of the crude acid chloride in dry THF (10 mL). After 
being stirred at the same temperature for 15 min, the reaction mixture was quenched with saturated 
aqueous NH4Cl. The organic layer was separated, and the aqueous layer was extracted with EtOAc. The 
combined organic layers were washed with brine, dried over MgSO4, and filtered. The filtrate was 
concentrated in vacuo, and the residue was purified by column chromatography on silica gel (eluted with 
hexane/EtOAc = 9:1) to afford the ketone 5 (1.20 g, 5.25 mmol, 99% over 2 steps) as a colorless oil. 
[α]19D +4.3 (c 0.97, CHCl3); 1H NMR (400 MHz, CDCl3) δ 4.02 (t, 2H, J = 6.7 Hz), 2.41−2.58 (m, 3H), 
2.34 (dd, 1H, J = 14.9, 5.8 Hz), 2.20 (dd, 1H, J = 14.9, 6.8 Hz), 1.60−1.69 (m, 2H), 1.12 (s, 9H), 
0.92−0.97 (m, 6H); 13C NMR (100 MHz, CDCl3) δ 214.6, 172.7, 65.8, 44.1, 42.7, 40.9, 26.3, 26.0, 22.0, 
19.9, 10.4; IR (neat) 2968, 2878, 1734, 1706, 1464, 1366, 1223, 1196, 1166, 1059 cm−1; HRMS[ESI] 
calcd for C13H24O3Na [M+Na]+ 251.1618, found 251.1616. 
Propyl (3R,5S)-5-hydroxy-3,6,6-trimethylheptanoate (6): To a solution of 
(R)-2-methyl-CBS-oxazaborolidine (87.3 µL, 0.0873 mmol, 1 M in toluene, 0.30 equiv), was added a 
solution of catecholborane (1.5 mL, 1.46 mmol, 1 M in THF, 5.0 equiv) at 0 °C under an argon 
atmosphere, and the mixture was stirred at the same temperature for 30 min. A solution of the ketone 5 
(66.4 mg, 0.291 mmol, 1.0 equiv) in dry toluene (0.6 mL) was then added to above mixture dropwise. 
After being stirred at 0 °C for 9 h, the reaction mixture was quenched with MeOH and saturated aqueous 
NH4Cl. The organic layer was separated, and the aqueous layer was extracted with EtOAc. The combined 
organic layers were washed with brine, dried over MgSO4, and filtered. The filtrate was concentrated in 
vacuo, and the residue was purified by column chromatography on silica gel (eluted with hexane/EtOAc 
= 15:1) to afford the alcohol 6 (58.9 mg, 0.256 mmol, 88%) as a colorless oil. The diastereomeric ratio of 
6 was determined by HPLC analysis (column: Senshu Pak Silica-3301-N (8Φ × 300 mm); flow rate: 1.0 
mL/min; elution rate: hexane/EtOAc = 3:1 (isocratic); retention time: 19.7 min for 6, 21.1 min for C5 
diastereomer of 6). [α]21D −34 (c 0.97, CHCl3); 1H NMR (400 MHz, CDCl3) δ 3.99−4.09 (m, 2H), 3.22 
(brd, 1H, J = 10.2 Hz), 2.41 (dd, 1H, J = 14.5, 5.4 Hz), 2.17−2.26 (m, 1H), 2.15 (dd, 1H, J = 14.5, 7.3 Hz), 
 
1.91 (brs, 1H), 1.61−1.70 (m, 2H), 1.27−1.44 (m, 2H), 1.03 (d, 3H, J = 6.6 Hz), 0.95 (t, 3H, J =7.4 Hz), 
0.89 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 173.8, 66.0, 40.6, 38.7, 34.8, 27.5, 25.6, 22.0, 21.5, 10.4; IR 
(neat) 3461, 2961, 2872, 1734, 1364, 1315, 1279, 1194, 1167, 1065 cm−1; HRMS[ESI] calcd for 
C13H27O3 [M+H]+ 231.1955, found 231.1954. 
(S)-5-(4-methoxybenzyloxy)-3,6,6-trimethylheptan-1-ol (7): To a solution of the alcohol 6 (100 mg, 
0.430 mmol, 1.0 equiv) in dry THF (2.2 mL) were added TriBOT-PM (318 mg, 0.650 mmol, 1.5 equiv) 
and a solution of BF3·OEt2 (220 µL, 0.0430 mmol, 200 mM in THF, 0.10 equiv) at 0 °C under an argon 
atmosphere. After being stirred at the same temperature for 5 h, the reaction mixture was quenched with 
saturated aqueous NaHCO3. The aqueous layer was extracted with EtOAc. The combined organic layers 
were washed with brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo, and the 
resulting residue was passed through a short pad of silica gel (eluted with hexane/EtOAc = 30:1). The 
resulting PMB ether was used for the next reaction without further purification. 
  To a solution of the above ester in dry CH2Cl2 (2.2 mL) was added a solution of DIBAL-H (1.1 mL, 
1.10 mmol, 1.0 M in hexane, 2.6 equiv) at 0 °C under an argon atmosphere. After being stirred at the 
same temperature for 10 min, the reaction mixture was quenched with MeOH and Rochelle salt at 0 °C, 
and stirred at room temperature for 1 h. The aqueous layer was extracted with EtOAc. The organic layer 
was washed with brine, dried over MgSO4, and filtered. The filtrate was concentrated in vacuo, and the 
residue was purified by column chromatography on silica gel (eluted with hexane/EtOAc = 20:1) to 
afford the alcohol 7 (107 mg, 0.380 mmol, 88% over 2 steps) as a colorless oil. The spectroscopic data of 
7 were in good agreement with those reported in the literature.10,11 [α]22D −31 (c 1.4, CHCl3); 
HRMS[ESI] calcd for C18H30O3Na [M+Na]+ 317.2087, found 317.2085. 
N-Fmoc derivative of H-Bph-MeAla-MeIle-OAllyl (9): To Boc-MeAla-MeIle-OAllyl6 (479 mg, 1.29 
mmol, 1.5 equiv) was added 4 M HCl/dioxane (6.7 mL) at 0 °C. After being stirred at room temperature 
for 6 h, the reaction mixture was concentrated in vacuo. The residue was azeotroped with toluene and 
CH2Cl2. The crude amine was used for the next reaction without further purification. 
   To a solution of the crude amine in dry CH2Cl2 (4.3 mL) were added Fmoc-Bph-OH (400 mg, 0.862 
mmol, 1.0 equiv), DIEA (676 µL, 3.88 mmol, 4.5 equiv) and HATU (490 mg, 1.29 mmol, 1.5 equiv) at 
room temperature under an argon atmosphere. After being stirred at the same temperature for 1 h, the 
reaction mixture was quenched with H2O at 0 °C. The organic layer was separated, and the aqueous layer 
was extracted with CHCl3. The combined organic layers were washed with brine, dried over MgSO4, and 
filtered. The filtrate was concentrated in vacuo, and the resulting residue was purified by column 
chromatography on silica gel (eluted with hexane/EtOAc = 4:1) to afford the tripeptide 
Fmoc-Bph-MeAla-MeIle-OAllyl (605 mg, 0.845 mmol, 98%) as a white amorphous solid. [α]23D −83 (c 
0.55, CHCl3); 1H NMR (600 MHz, CDCl3, major rotamer) δ 7.72−7.78 (m, 2H), 7.27−7.56 (m, 15H), 
 
5.85−5.91 (m, 1H), 5.53 (d, 1H, J = 8.9 Hz), 5.43 (q, 1H, J = 6.8 Hz), 5.17−5.32 (m, 2H), 4.97−5.02 (m, 
1H), 4.92 (d, 1H, J = 10.3 Hz), 4.52−4.62 (m, 2H), 4.28−4.43 (m, 2H), 4.13−4.20 (m, 1H), 3.13 (dd, 1H, J 
= 13.7, 7.2 Hz), 3.00 (s, 3H), 2.93 (dd, 1H, J = 13.7, 6.8 Hz), 2.75 (s, 3H), 1.88−1.95 (m, 1H), 1.29 (d, 3H, 
J = 6.8 Hz), 1.18−1.28 (m, 1H), 0.90−0.96 (m, 1H), 0.89 (d, 3H, J = 6.8 Hz), 0.77 (t, 3H, J = 7.6 Hz); 13C 
NMR (150 MHz, CDCl3, mixture of rotamers) δ 171.8, 171.3, 170.6, 155.7, 143.8, 143.7, 141.3, 140.7, 
140.6, 139.9, 135.5, 135.1, 131.7, 129.9, 128.8, 127.7, 127.2, 127.1, 126.9, 125.1, 120.0, 118.7, 67.0, 65.4, 
60.5, 52.1, 49.7, 47.1, 38.6, 34.4, 33.2, 31.0, 30.6, 25.0, 16.1, 15.7, 14.3, 11.6, 10.5; IR (neat) 3293, 2965, 
1734, 1647, 1486, 1450, 1246, 760, 741 cm−1; HRMS[ESI] calcd for C44H49N3O6Na [M+Na]+ 738.3514, 
found 738.3502. 
Preparation of H-Bph-MeAla-MeIle-OAllyl (9): To a solution of the above N-Fmoc tripeptide (169 mg, 
0.236 mmol, 2.0 equiv) in dry MeCN (9.4 mL) was added Et2NH (4.7 mL) at room temperature under an 
argon atmosphere. After being stirred at the same temperature for 50 min, the reaction mixture was 
concentrated in vacuo. The residue was azeotroped twice with CH2Cl2. The resulting amine 9 was used 
for the next reaction without purification. 
Hexadepsipeptide 10: To a solution of the allyl ester 810,11 (86.4 mg, 0.118 mmol, 1.0 equiv) in dry THF 
(2.0 mL) were added N-methylaniline (32.0 µL, 0.295 mmol, 2.5 equiv) and a catalytic amount of 
Pd(PPh3)4 (13.6 mg, 0.0118 mmol, 0.01 equiv) at 0 °C under an argon atmosphere. After being stirred at 
room temperature for 1.5 h, the reaction mixture was concentrated in vacuo. The residue was passed 
through a short pad of silica gel (eluted with hexane/EtOAc = 4:1, then CH2Cl2/MeOH = 9:1). The 
resulting carboxylic acid was used for the next reaction without further purification. 
   To a solution of the above-mentioned amine 9 in dry CH2Cl2 (1.0 mL) were added a solution of the 
above carboxylic acid in dry CH2Cl2 (1.0 mL), DIEA (62.0 µL, 0.354 mmol, 3.0 equiv) and HATU (67.0 
mg, 0.177 mmol, 1.5 equiv) at 0 °C under an argon atmosphere. After being stirred at room temperature 
for 1 h, the reaction mixture was concentrated in vacuo. The residue was purified by column 
chromatography on silica gel (eluted with hexane/acetone = 9:1) to afford the hexadepsipeptide 10 (137 
mg, 0.117 mmol, 99% over 2 steps) as a white amorphous solid. [α]19D −1.0 X 102 (c 0.25, CH2Cl2); 1H 
NMR (600 MHz, CD2Cl2, major rotamer) δ 7.25−7.79 (m, 17H), 6.49−6.60 (m, 1H), 6.30 (d, 1H, J = 8.6 
Hz), 5.86−5.94 (m, 1H), 5.08−5.42 (m, 5H), 4.79−4.92 (m, 2H), 4.58 (m, 2H), 4.12−4.47 (m, 3H), 
3.31−3.76 (m, 5H), 2.61−3.20 (m, 10H), 0.76−2.31 (m, 39H); 13C NMR (150 MHz, CD2Cl2 mixture of 
rotamers) δ 172.8, 172.0, 171.4, 170.8, 168.2, 155.2, 144.7, 144.5, 141.7, 141.6, 140.9, 140.0, 136.0, 
132.4, 130.4, 129.1, 128.0, 127.9, 127.6, 127.4, 127.3, 127.2, 125.8, 125.7, 125.6, 120.2, 118.6, 78.7, 71.7, 
68.0, 67.9, 65.6, 60.9, 60.1, 50.7, 50.1, 47.6, 47.5, 46.9, 46.1, 39.4, 38.4, 38.2, 37.9, 35.0, 34.9, 33.4, 31.5, 
31.2, 30.8, 30.3, 26.1, 26.0, 25.4, 25.3, 24.9, 23.6, 20.5, 20.4, 16.5, 15.8, 15.7, 14.5, 13.7, 13.6, 10.5; IR 
 
(neat) 3477, 3327, 2963, 2931, 2875, 1738, 1706, 1644, 1486, 1451, 1416, 1364, 1274, 1181, 1123, 1087, 
988, 760, 740 cm−1; HRMS[ESI] calcd for C68H88N5O10S [M+H]+ 1166.6246, found 1166.6224. 
Apratoxin A’s Bph analogue (3): To a solution of the allyl ester 10 (130 mg, 0.111 mmol, 1.0 equiv) in 
dry THF (2.0 mL) were added N-methylaniline (32.0 µL, 0.295 mmol, 2.7 equiv) and a catalytic amount 
of Pd(PPh3)4 (13.6 mg, 0.0118 mmol, 0.11 equiv) at 0 °C under an argon atmosphere. After being stirred 
at room temperature for 40 min, the reaction mixture was concentrated in vacuo. The residue was passed 
through a short pad of silica gel (eluted with hexane/EtOAc = 4:1, then CH2Cl2/MeOH = 9:1). The 
resulting carboxylic acid was used for the next reaction without further purification. 
   To a solution of the above N-Fmoc amine in dry MeCN (4.7 mL) was added Et2NH (2.4 mL) at 0 °C 
under an argon atmosphere. After being stirred at room temperature for 1.5 h, the reaction mixture was 
concentrated in vacuo. The residue was azeotroped twice with CH2Cl2. The crude cyclization precursor 
was used for the next reaction without further purification. 
   To a solution of the crude cyclization precursor in dry CH2Cl2 (118 mL) were added DIEA (183 µL, 
1.06 mmol, 9.5 equiv) and HATU (134 mg, 0.354 mmol, 3.2 equiv) at 0 °C under an argon atmosphere. 
After being stirred at room temperature for 14 h, the reaction mixture was concentrated in vacuo. The 
residue was purified by column chromatography on silica gel (eluted with hexane/EtOAc = 4:1, then 
CH2Cl2/MeOH = 9:1) and subsequent reversed-phase HPLC (column: YMC-Pack R&D ODS-A 20 mm × 
150 mm; flow rate: 10.0 mL/min; elution method: H2O/MeOH = 20:80−0:100 linear gradient (0.0−10.0 
min), H2O/MeOH = 0:100 isocratic (10.0−20.0 min); retention time: 12.4 min) to afford apratoxin A’s 
Bph analogue (3) (34.6 mg, 0.0390 mmol, 35% over 3 steps) as a white amorphous solid. [α]27D −2.2 X 
102 (c 0.58, MeOH); 1H NMR (600 MHz, CD3CN, major rotamer) δ 7.34−7.63 (m, 9H), 6.56−6.67 (m, 
1H), 6.11−6.19 (m, 1H), 5.24−5.29 (m, 1H), 5.10 (d, 1H, J = 11.7 Hz), 4.98−5.10 (m, 1H), 4.94 (dd, 1H, J 
= 13.0, 1.8 Hz), 4.51 (d, 1H, J = 11.0 Hz), 4.04−4.12 (m, 2H), 2.95−3.62 (m, 7H), 2.92 (s, 3H), 2.53−2.63 
(m, 4H), 2.22−2.30 (m, 1H), 1.99−2.19 (m, 3H), 1.94 (s, 3H), 1.74−1.88 (m, 3H), 1.48−1.54 (m, 1H), 
1.13−1.36 (m, 3H), 1.07 (d, 3H, J = 6.5 Hz), 1.03 (d, 3H, J = 7.2 Hz), 0.94 (d, 3H, J = 6.5 Hz), 0.87 (s, 
9H), 0.82−0.86 (m, 7H); 13C NMR (150 MHz, CD3CN, major rotamer) δ 176.8, 173.3, 171.9, 171.2, 
170.7, 170.0, 141.5, 140.2, 137.4, 136.7, 131.00, 130.96, 129.8, 128.2, 127.74, 127.66, 77.9, 73.0, 72.2, 
61.4, 60.6, 57.2, 51.2, 50.1, 48.4, 38.9, 38.3, 37.6, 37.4, 35.6, 32.4, 30.5, 30.1, 26.2, 26.1, 25.6, 25.1, 19.8, 
16.9, 14.4, 14.3, 13.4, 9.2; IR (neat) 3421, 2965, 2931, 2874, 1740, 1624, 1486, 1455, 1392, 1371, 1319, 
1277, 1219, 1178, 1116, 1078, 733, 699 cm−1; HRMS[ESI] calcd for C50H72N5O7S [M+H]+ 886.5147, 
found 886.5128. 
Cytotoxicity Assay. Human colorectal carcinoma HCT-116 cells were kindly provided by Prof. 
Yoshiteru Oshima at the Graduate School of Pharmaceutical Sciences in Tohoku University. They were 
cultured in an RPMI 1640 medium (Nacalai Tesque, Inc., Kyoto, Japan) containing 10% fetal bovine 
 
serum (Equitech-Bio, Inc., Texas, USA), 100 U/mL of penicillin, and 100 mg/mL of streptomycin 
(Nacalai Tesque, Inc., Kyoto, Japan) at 37 °C under 5% CO2. For the cytotoxicity assay, near-confluent 
cultures of the cells were plated at 5 × 103 cells/100 µL/well fresh culture medium in a 96-well clear 
bottom plate and incubated at 37 °C under 5% CO2 for 24 h before the assays. 
   Each compound was dissolved in DMSO at concentrations ranging from 0.01 to 100 µM. One 
microliter of the resultant solution was added to the above-mentioned 100 µL cell culture, resulting in 
various concentrations of the compound (0.1 – 1000 nM) or solvent control (DMSO 1%). After a 48 h 
incubation at 37 °C under 5% CO2, 10 µL of WST-8 reagent solution (Cell Count Reagent SF, Nacalai 
Tesque, Inc.)14 was added to the cell culture. The cell culture was then incubated at 37 °C under 5% CO2 
for 2 h. Colorimetric determination of WST-8 was conducted at 450 nm with an optional reference 
wavelength at 595 nm using a microplate reader (Model 680, Bio-Rad, Hercules, CA). The absorbance 
obtained upon the addition of the vehicle was considered as 100%. Data are expressed from the dose–
response curves at three independent experiments. IC50 values were calculated by probit analysis using 
the PriProbit 1.63 software.15 
Molecular Modeling Based on NMR Data. A NMR measurement for 3D structural analysis was 
conducted using a NMR spectrometer (600 MHz for 1H) at 298 K using compound 3. 3JH,H values were 
determined by 1D 1H spectra and 1H-1H J-resolved 2D NMR spectra. According to a J-based 
configuration analysis (JBCA) method,16 3JH,H coupling constants for clearly anti-oriented vicinal protons 
(3JH,H ≥ 10 Hz) were interpreted as torsional angle constraints. 
   Molecular modeling was performed on the MacroModel (version 9.9) program17 by the distance 
geometry method. We used an OPLS-2005 force field and a generalized Born/solvent-accessible surface 
area (GB/SA) solvent model.18 The calculations were conducted in a chloroform environment. To find 3D 
structures that were in agreement with the experimental data and also had low energies in a given force 
field, we selected a protocol that comprised two steps. First, a conformational search was performed using 
Monte Carlo-based torsional sampling with the above torsional angle constraints at 20,000 iterations with 
500 times of energy minimization. Then, energy minimization was applied to each found structure 
without constraints. 
ACKNOWLEDGEMENTS 
This work was supported by JSPS KAKENHI, Grant no. JP15H05837 (Grant-in-Aid for Scientific 
Research on Innovative Areas: Middle Molecular Strategy), and the Platform Project for Supporting in 
Drug Discovery and Life Science Research from AMED under Grant No. JP18am0101095 and 
JP18am0101100. The authors are grateful to Profs. Yoshiteru Oshima and Haruhisa Kikuchi at the 
Graduate School of Pharmaceutical Sciences in Tohoku University for allowing us to use their facility for 
 
the cell-based assay. The authors also thank MARUZEN-YUSHODO Co., Ltd. for the English language 
editing. 
REFERENCES AND NOTES 
1. H. Luesch, W. Y. Yoshida, R. E. Moore, V. J. Paul, and T. H. Corbett, J. Am. Chem. Soc., 2001, 123, 
5418. 
2. K. Tidgewell, N. Engene, T. Byrum, J. Media, T. Doi, F. A. Valeriote, and W. H. Gerwick, 
ChemBioChem, 2010, 11, 1458. 
3. K.–C. Huang, Z. Chen, Y. Jiang, S. Akare, D. Kolber-Simonds, K. Condon, S. Agoulnik, K. 
Tendyke, Y. Shen, K.–M. Wu, S. Mathieu, H.–w. Choi, X. Zhu, H. Shimizu, Y. Kotake, W. H. 
Gerwick, T. Uenaka, M. Woodall-Jappe, and K. Nomoto, Mol. Cancer Ther., 2016, 15, 1208. 
4. Q.–Y. Chen, Y. Liu, and H. Luesch, ACS Med. Chem. Lett., 2011, 2, 861; Q.–Y. Chen, Y. Liu, W. 
Cai, and H. Luesch, J. Med. Chem., 2014, 57, 3011; W. Cai, Q.–Y. Chen, L. H. Dang, and H. Luesch, 
ACS Med. Chem. Lett., 2017, 8, 1007 and 1342 (correction); W. Cai, R. Ratnayake, M. H. Gerber, 
Q.–Y. Chen, Y. Yu, H. Derendorf, J. G. Trevino, and H. Luesch, Invest. New Drugs, 2019, 37, 364. 
5. Y. Onda, Y. Masuda, M Yoshida, and T. Doi, J. Med. Chem., 2017, 60, 6751; T. Doi, Y. Masuda, 
and M. Yoshida, J. Synth. Org. Chem., Jpn., 2018, 76, 1170. 
6. J. Chen and C. J. Forsyth, J. Am. Chem. Soc., 2003, 125, 8734; J. Chen and C. J. Forsyth, Proc. Natl. 
Acad. Sci., U.S.A., 2004, 101, 12067; T. Doi, Y. Numajiri, A. Munakata, and T. Takahashi, Org. 
Lett., 2006, 8, 531; T. Doi, Chem. Pharm. Bull., 2014, 62, 735; D. Ma, B. Zou, G. Cai, X. Hu, and J. 
O. Liu, Chem. Eur. J., 2006, 12, 7615; E. J. Rastelli, and D. M. Coltart, Tetrahedron, 2018, 74, 
2269. 
7. M. Yoshida, Y. Onda, Y. Masuda, and T. Doi, Biopolymers (Peptide Science), 2016, 106, 404; Y. 
Masuda, J. Suzuki, Y. Onda, Y. Fujino, M. Yoshida, and T. Doi, J. Org. Chem., 2014, 79, 8000. 
8. E. J. Corey, R. K. Bakshi, and S. Shibata, J. Am. Chem. Soc., 1987, 109, 5551; E. J. Corey, R. K. 
Bakshi, S. Shibata, C.–P. Chen, and V. K. Singh, J. Am. Chem. Soc., 1987, 109, 7925; E. J. Corey, S. 
Shibata, and R. K. Bakshi, J. Org. Chem., 1988, 53. 2861; E. J. Corey and R. K. Bakshi, 
Tetrahedron Lett., 1990, 31, 611. 
9. K. Yamada, H. Fujita, and M. Kunishima, Org. Lett., 2012, 14, 5026; K. Yamada, H. Fujita, M. 
Kitamura, and M. Kunishima, Synthesis, 2013, 45, 2989. 
10. Z. Xu, Z. Chen, and T. Ye, Tetrahedron Asymmetry, 2004, 15, 355. 
11. Y. Numajiri, T. Takahashi, and T. Doi, Chem. Asian J., 2009, 4, 111. 
12. T. Doi, Y. Numajiri, T. Takahashi, M. Takagi, and K. Shin-ya, Chem. Asian J., 2011, 6, 180; Y. 
Numajiri, T. Doi, and T. Takahashi, Chem. Asian J., 2009, 4, 111. 
13. A. O. Paatero, J. Kellosalo, B. M. Dunyak, J. Almaliti, J. E. Gestwicki, W. H. Gerwick, J. Taunton, 
and V. O. Paavilainen, Cell Chem. Biol., 2016, 23, 561. 
14. M. Ishiyama, Y. Miyazono, K. Sasamoto, Y. Ohkura, and K. Ueno, Talanta, 1997, 44, 1299; H. 
Tominaga, M. Ishiyama, F. Ohseto, K. Sasamoto, T. Hamamoto, K. Suzuki, and M. Watanabe, Anal. 
Commun., 1999, 36, 47. 
15. M. Sakuma, Appl. Entomol. Zool., 1998, 33, 339. 
 
16. N. Matsumori, D. Kaneno, M. Murata, H. Nakamura, and K. Tachibana, J. Org. Chem., 1999, 64, 
866. 
17. F. Mohamadi, N. G. J. Richards, W. C. Guida, R. Liskamp, M. Lipton, C. Caufield, G. Chang, T. 
Hendrickson, and W. C. Still, J. Comput. Chem., 1990, 11, 440; W. C. Still, A. Tempczyk, R. C. 
Hawley, and T. Hendrickson, J. Am. Chem. Soc., 1990, 112, 6127; Schrödinger Suite 2012: 
MacroModel, version 9.9, Schrödinger, LLC, New York, NY, 2012. 
18. D. Qiu, P. S. Shenkin, F. P. Hollinger, and W. C. Still, J. Phys. Chem. A, 1997, 101, 3005. 
 
 
